Bayer Inc. v. Amgen Canada Inc.
The Federal Court held that the 276 Patent was ineligible for listing because Claim 58 did not claim the very change in use approved by the SNDS-related NOC.
- Pmnoc regulations
- Patent listing eligibility
- Claim construction
- Abbott test
- Notice of compliance
- Biosimilar regulatory stay